Journey Medical 3Q 2026: Revenue $18.97M, EPS ($0.05) — 10-Q Summary

Journey Medical reported 3Q 2026 revenue of $18.97M, up 8% YoY, with net loss narrowing 43% to $1.32M. Emrosi sales grew 84% YoY to $9.0M, while Qbrexza and legacy products saw declines. The company paid $4.1M in vendor settlements.

Original reporting
Published Nov 12, 2026, 9:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Journey Medical 3Q 2026: Revenue $18.97M, EPS ($0.05) — 10-Q Summary — source image
Decision brief

The 30-second read

$DERMNeutralLow
01

Why it matters

The earnings release adds a fresh data point for the company but lacks a transformative catalyst; market reaction is expected to be muted.

02

Market read

Micro‑cap earnings release with modest financial improvement; limited immediate trading impact.

03

What to watch

Potential impact of the vendor settlement expense on cash flow and future profitability.

Relevance 6/10Novelty 6/10Timing: post‑market release

Background

Journey Medical Corp (NASDAQ: DERM) filed its Form 10‑Q for Q3 2026, showing incremental revenue growth and a significant reduction in net loss.

Company-level read

Ticker impact

$DERMNeutralHigh confidence
Context

Journey Medical reported Q3 2026 revenue of $18.97M and a narrowed net loss, marking its first public disclosure of these quarterly results.

Expected impact

limited upside as investors digest modest improvement; likely modest price stability.

Evidence & confidence

The numbers are new but small in absolute terms; no major guidance change or catalyst to drive a strong move.

Market effects

Provides a modest data point for the dermatology device sector but unlikely to shift sector sentiment.

Limited to U.S. micro‑cap investors; no broader regional effect.

Minimal global relevance given the company's size and niche market.

Counterpoint

If the loss narrowing continues, the stock could be undervalued relative to peers.

Key entities

  • Journey Medical Corp

    Dermatology device manufacturer reporting Q3 2026 results.

Related articles

$DERMMed

Journey Medical Corporation Reports Third Quarter 2026 Financial Results and Recent Corporate

Journey Medical Corp (DERM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Journey Medical Corporation Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights Total revenues were $19.0 million for the third quarter of 2026 Emrosi ® revenues of $9.0 million increased 84% compared to the third quarter of 2025 Company to h

$DERMMedAI 8/10

Why is Journey Medical stock rallying today?

Journey Medical Corp (DERM) shares rose 10.9% pre-open after it reported Q2 2026 results. Adjusted EPS was $0.10 vs a $0.02 loss estimate, and revenue was $18.5M vs $18.37M forecast, up 23% YoY. Emrosi sales were $8.1M; GAAP net loss narrowed to about $312k. Company expects positive adjusted EBITDA for 2026.

$DERMMed

Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate

Journey Medical Corp (DERM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter Emrosi ® revenues were $8.1 million for the s

$NVDAHighAI 9/10

Nvidia's $130 Billion Forecast Sparks Fresh AI Stock Rally

Nvidia's shares rose 2% premarket after reporting Q3 sales of $115.84B, up 4x, and raising its fiscal 2028 sales growth target to ~75%. The company also guided to a gross margin of 71-72% for the current quarter. AI-related stocks also gained. Nvidia's board is searching for a permanent CEO after rejecting Jensen Huang's return. The company excluded future China shipments from its projections.